In addition, we investigated the diagnostic accuracy using the area under the ROC curve (AUROC) of BGM for patients diagnosed with MS compared to healthy donors of 0.717 (95%CI: 0.547–0.888, p = 0.028, Figure 1D), NIC for patients diagnosed with MS compared to healthy donors of 0.765 (95%CI: 0.601–0.928, p = 0.005, Figure 1E), SPARC-M for patients diagnosed with MS compared to healthy donors of 0.875 (95%CI: 0.764–0.987, p < 0.0001, Figure 1F). Here, SPARC is linked to myeloid sarcoma.